FDA Disagrees With GAO’s “Unusual” Findings Regarding Plan B Decision
This article was originally published in The Tan Sheet
Executive Summary
Reports from FDA officials vary as to the timing of the decision not to approve Barr's emergency contraceptive Plan B for over-the-counter sale, GAO's investigation into the application process reveals (see chart: "1Brief Timeline of Major Plan B Events Related to the Initial OTC Switch Application").You may also be interested in...
Wisconsin Citizen Petition Seeks Plan B Approval For All Ages
The State of Wisconsin has filed a citizen petition to persuade FDA to move Barr Labs' Plan B and any equivalent emergency contraceptives to OTC status without an age restriction
Wisconsin Citizen Petition Seeks Plan B Approval For All Ages
The State of Wisconsin has filed a citizen petition to persuade FDA to move Barr Labs' Plan B and any equivalent emergency contraceptives to OTC status without an age restriction
Wisconsin Citizen Petition Seeks Plan B Approval For All Ages
The State of Wisconsin has filed a citizen petition to persuade FDA to move Barr Labs' Plan B and any equivalent emergency contraceptives to OTC status without an age restriction
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: